Lexette, a potent topical corticosteroid, was initially approved by the Food and Drug Administration (FDA) in May 2018. The product was evaluated in 2 multicenter, randomized, double-blind, vehicle-controlled studies (N=560); study participants had plaque psoriasis involving between 2% to 12% body surface area. Lexette or vehicle foam was applied to all affected areas twice daily for up to 14 days.
The primary measure of efficacy was Overall Treatment Success, defined as the proportion of patients who were cleared or almost cleared with at least a 2-grade improvement from baseline at Week 2. In Study 1 (NCT02368210), success was observed in 25% of Lexette-treated patients vs 4% of patients in the vehicle foam arm. In Study 2 (NCT02742441), success was observed in 31% of Lexette-treated patients vs 7% with vehicle foam.
“Lexette is an elegant foam formulation that will give psoriasis patents more treatment options. The foam delivery platform has a well-established reputation with dermatologists due to ease of application and lack of greasiness and stickiness, especially in hair-bearing areas and under clothing,” stated Mayne Pharma CEO, Scott Richards.
Lexette is supplied as a 0.05% foam in 50g cans as 1- and 2-count cartons.
For more information call (833) 654-5188 or visit MaynePharma.com.